A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC

Introduction: Evidence supports the addition of immunotherapy to definitive chemoradiation for unresectable stage IIIA NSCLC. Adding pembrolizumab to neoadjuvant chemoradiation in patients with resectable stage IIIA NSCLC requires study for safety and feasibility. Methods: Patients with resectable s...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Christopher A. Lemmon, MD, Gregory M.M. Videtic, MDCM, Sudish Murthy, MD, PhD, Kevin L. Stephans, MD, Marc Shapiro, MD, Usman Ahmad, MD, Daniel Raymond, MD, Vamsidhar Velcheti, MD, Alejandro Bribriesco, MD, Xuefei Jia, MS, James Stevenson, MD, Nathan A. Pennell, MD, PhD
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2022-07-01
Serija:	JTO Clinical and Research Reports
Teme:	Neoadjuvant Chemoradiation Immunotherapy NSCLC
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2666364322000832
Oznake:	Označite Brez oznak, prvi označite!